BNC105

Generic Name: BNC105

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁O_₁₀P

CAS Number: 945772-45-2

Unique Ingredient Identifier: TO9V2XZF53

Indication: Investigated for use/treatment in cancer/tumors (unspecified).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer Metastatic

Interventions: Drug: Nivolumab 10 MG/ML
Drug: BBI608
Drug: BNC 105

First Posted Date: 2018-08-27

Last Posted Date: 2021-08-27

Lead Sponsor: Australasian Gastro-Intestinal Trials Group

Target Recruit Count: 90

Registration Number: NCT03647839

Locations: 🇦🇺
Eastern Health, Box Hill, Victoria, Australia
🇦🇺
Westmead Hospital, Westmead, New South Wales, Australia
🇦🇺
Ballarat Health Service, Ballarat, Victoria, Australia

and more 11 locations

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy